… [33] summarized a number of literatures on tocilizumab treatment of Takayasu arteritis and
found that its use could reduce (or even stop) the dosage of glucocorticoids. Samson et al. [34…

… patients treated with tocilizumab.8 Candidaemia with candidal endophthalmitis and endocarditis
was reported in 3 of the 43 severe COVID-19 patients treated with tocilizumab in Italy.9 …

… related to the treatment with tocilizumab, possibly causing an … early subcutaneous treatment
with tocilizumab are definitely … more that patients treated with subcutaneous tocilizumab for …

… The aim of this systematic review was to describe the rationale for the use of tocilizumab
for the treatment of COVID-19 and to summarize the available evidence regarding its efficacy …

… perforation during tocilizumab treatment, the possible role of the concomitant treatment with
… Nevertheless, we acknowledge that data on the efficacy of tocilizumab are still preliminary …

… Regarding laboratory results, if one or more laboratory test resulted to statistically differ
between tocilizumab and standard treatment group with a potential clinical relevance, we were …

… Indeed, the IL-6-receptor antagonist tocilizumab, already approved for treatment of … So
far, the growing body of studies assessing the efficacy and safety of tocilizumab for treatment of …

… The retrospective study included 15 patients who were treated with tocilizumab from Jan 27
… The rational use of the tocilizumab in severe and critically ill COVID-19 patients can prevent …

… the efficacy of IL-6 blockers such as tocilizumab in treating critical COVID-19 patients [24-26].
Tocilizumab is approved by the FDA to treat rheumatoid arthritis, giant cell arteritis, poly-…

… study was lower in patients treated with tocilizumab in the first 2 days of ICU admission
compared with patients whose treatment did not include early use of tocilizumab. However, the …